Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: A new action for an old drug

Journal of Clinical Investigation

Volumn 98, Issue 6, 1996, Pages 1465-1470

  Münzel, Thomas ^a,c   Kurz, Sabine ^a   Rajagopalan, Sanjay ^a   Thoenes, Martin ^c   Berrington, William R ^a,b   Thompson, J Anthony ^b   Freeman, Bruce A ^b   Harrison, David G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

acetylcholine; lucigenin chemiluminescence; nitrate tolerance; nitric oxide; superoxide

Indexed keywords

GLYCERYL TRINITRATE; HYDRALAZINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TOLERANCE; FEMALE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT;

EID: 0029780286     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118935     Document Type: Article

References (30)

1. Abrams, J. 1988. A reappraisal of nitrate therapy. JAMA (J. Am. Med. Assoc.). 259:396-401.
2. Münzel, T., H. Sayegh, B.A. Freeman, M.M. Tarpey, and D.G. Harrison. 1995. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism of tolerance and cross tolerance. J. Clin. Invest. 95:187-194.
3. Mohazzab, K.M., and M.S. Wolin. 1994. Sites of superoxide anion production detected by lucigenin in calf pulmonary artery smooth muscle. Am. J. Physiol. 267:L815-L822.
4. Mohazzab-H, K.M., P.M. Kaminski, and M.S. Wohn. 1994. NADH oxidoreductase is a major source of superoxide anion in bovine coronary endothelium. Am. J. Physiol. 266:H2568-H2572.
5. Griendling, K., J.D. Ollerenshaw, C.A. Minieri, and R.W. Alexander. 1994. Angiotensin II stimulates NADH and NADPH activity in cultured vascular smooth muscle cells. Circ Res. 74:1141-1148.
6. Rajagopalan, S., S. Kurz, T. Münzel, M. Tarpey, B.A. Freeman, K.K. Griendling, and D.G. Harrison. 1996. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97:1916-1923.
7. Bauer, J.A., and H.L. Fung. 1991. Concurrent hydralazine administration prevents nitroglycerin induced hemodynamic tolerance in experimental heart failure. Circulation. 84:35-39.
8. Ohara, Y., T.E. Peterson, and D.G. Harrison. 1993. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 91: 2546-2551.
9. Kooy, N.W., and J.A. Royall. 1994. Agonist-induced peroxynitrite production from endothelial cells. Arch. Biochem. Biophys. 310:352-359.
10. McCord, J.M. and M.I. Fridovich. 1969. Superoxide dismulase. J. Biol. Biochem. 244:6049-6055.
11. Bradford, M.M. 1976. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
12. Hermsmeyer, K.A., A. Trapani, P.W. Aberl, and M. Worcel. 1983. Effect of hydralazine on tension and membrane potential in the rat caudal artery. J. Pharmacol. Exp. Ther. 227:322-326.
13. Griendling, K., J.D. Ollerenshaw, C.A. Minieri, and R.W. Alexander. 1993. Angiotensin II stimulates superoxide production in cultured vascular smooth muscle cells. FASEB (Fed. Am. Soc. Exp. Biol.) J. 7:5a.( Abstr.).
14. Cross, A.R., and O.T. Jones. 1986. The effect of the inhibitor diphenylene iodonium on the superoxide-generating system of neutrophils. Specific labelling of a component polypeptide of the oxidase. Biochem. J. 237:111-116.
15. Rajagopalan, S., K. Griendling, and D.G. Harrison. 1995. Angiotensin II increases vascular superoxide anion production in vivo. FASEB(Fed. Am. Soc. Exp. Biol.) J. 9:315a. (Abstr.)
16. Kurz, S., T. Münzel, D. Harrison. 1995. A role for angiotensin II in nitrate tolerance: chronic AT-1 receptor blockade prevents development of tolerance and cross tolerance. Circulation. 82(Suppl. 1):1867a. (Abstr.)
17. Radi, R., H. Rubbo, K. Bush, and B.A. Freeman. 1996. Xanthine oxidase binding to glycosaminoglycans: kintetics and superoxide dismutase interactions of the immobilized xanthine oxidase-heparin complexes. Arch. Biochem. Biophys. In press.
18. Gogia, H., A. Mehra, S. Parikh, J. Ajit-Uppal, J. Johnson, and U. Elkayam. 1994. A randomaized study to evaluate the effect of hydralazine on the development of nitrate tolerance in patients with heart failure. Circulation. 90:1-601a.(Abstr.)
19. Bauer, J.A., and H.L. Fung. 1991 Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation. 84:35-39.
20. Cohn, J.N., D.G. Archibald, S. Ziesche, J.A. Franciosa, W.E. Harston, F.E. Tristani, W.B. Dunkman, W. Jacobs, G.S. Francis, K.H. Flohr, et al. 1986. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. 314: 1547-1552.
21. Cohn, J.N., G. Johnson, S. Ziesche, F. Cobb, G. Francis, F. Tristani, R. Smith, W.B. Dunkman, H. Loeb, M. Wong, et al. 1991. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure [see comments]. N. Engl. J. Med. 325:303-310.
22. Campbell, W.B., R.M. Graham, E.K. Jackson, D.P. Loisel, and W.A. Pettinger. 1980. Effect of indomethacin on hydralazine-induced renin and catecholamine release in the conscious rabbit. Br. J. Pharmacol. 71:529-531.
23. Packer, M., W. Lee, P.D. Kessler, S.S. Gottlieb, N. Medina, and M. Yushak. 1987. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N. Engl. J. Med. 317:799-804.
24. Parker, J.O., and J.D. Parker. 1992. Neurohormonal activation during nitrate therapy: a possible mechanism for tolerance [Review]. Am. J. Cardiol. 70:24.
25. Kishi, H., T. Kishi, and K. Folkers. 1975. Bioenergetics in clinical medicine. III. Inhibition of conezyme Q10-enzymes by clinically used antihypertensive agents. Res. Commun. Chem. Pathol. Pharmacol. 12:533-540.
26. Johnson, C., C. Stubley-Beedham, and J.G.S. Stell. 1985. Hydralazine: a potent inhibitor of the aldehyde oxidase activity in vivo and in vitro. Biochem. Pharmacol. 34:4251-4256.
27. Atwal, K.S. 1994. Pharmacology and structure-activity relationships for KATP modulators: tissue-selective KATP openers. J. Cardiovasc. Pharmacol. 24:S12-S17.
28. Tsutamoto, T., M. Kinoshita, T. Hisanga, Y. Maeda, K. Maeda, A. Wada, D. Fukai, and S. Yoshida. 1995. Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure. Am. J. Cardiol. 75:1162-1165.
29. Tsutamoto, T., M. Kinoshita, I. Nakae, Y. Maeda, A. Wada, T. Yabe, and H. Horie. 1994. Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. Am. Heart J. 127:866-873.
30. Bassenge, E., B. Fink, O. Sommer, and C. Huckstorf. 1994. Long term increases in coronary arterial conductance during five days infusion of low dose nicorandil. J. Cardiovasc. Pharmacol. 28:912-916.